{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:23:09Z","timestamp":1790090589544,"version":"4.0.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Fondazione Pezzoli per la Malattia di Parkinson, Milan, Italy"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Parkinson's disease (PD) causes disability and premature mortality if untreated. Limited access to levodopa in low- and middle-income countries leaves many patients undertreated.\n                      <jats:italic toggle=\"yes\">Mucuna pruriens<\/jats:italic>\n                      (MP) is a leguminous plant that contains high concentrations of levodopa.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To demonstrate the non-inferiority of long-term intake of MP powder in terms of safety and efficacy compared to standard levodopa\n                      <jats:italic toggle=\"yes\">plus<\/jats:italic>\n                      dopa-decarboxylase inhibitor (LD\u2009+\u2009DDCI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this 12-month, multicenter, randomized, open-label phase 2 trial, thirty-two untreated PD patients received levodopa monotherapy with MP powder -derived from roasted seeds without pharmacological processing- or standard LD\u2009+\u2009DDCI. Dosing was adjusted for body weight and disease stage, with MP doses further calibrated to account for the absence of a DDCI. We measured quality of life using the 39-item PD Questionnaire, motor and non-motor disability using the Movement Disorders Society updated version of the Unified PD Rating Scale (MDS-UPDRS) (parts I to IV) and the Non-Motor Symptoms Questionnaire. Safety measures included recording any adverse event and laboratory test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MP powder improved quality of life, motor and non-motor symptoms over 12 months, demonstrating similar outcome to LD\u2009+\u2009DDCI on all endpoints. Adverse events were more frequent with MP (56% vs. 37.5%, p\u2009=\u20090.48), though the difference was not statistically significant. Most were mild, with only 12.5% leading to discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MP could be a cost-effective alternative for PD individuals with limited access to commercial levodopa formulations. To confirm long-term safety and efficacy, larger international multicenter, double-blind trials with extended follow-up (e.g. 24\u201336 months) and ethnically diverse cohorts are needed.<\/jats:p>\n                    <jats:p>Registered at PACTR201611001882367<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x251383721","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:17:52Z","timestamp":1763749072000},"page":"99-109","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["<i>Mucuna pruriens<\/i>\n                    in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-1939","authenticated-orcid":false,"given":"Roberto","family":"Cilia","sequence":"first","affiliation":[{"name":"Fondazione IRCCS Istituto Neurologico Carlo Besta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momodou","family":"Cham","sequence":"additional","affiliation":[{"name":"Richard Novati Catholic Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Obese","sequence":"additional","affiliation":[{"name":"Komfo Anokye Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Akpalu","sequence":"additional","affiliation":[{"name":"Korle Bu Teaching Hospital"},{"name":"University of Ghana Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cereda","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Policlinico San Matteo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elikem","family":"Ame-Bruce","sequence":"additional","affiliation":[{"name":"Richard Novati Catholic Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-6145","authenticated-orcid":false,"given":"Ruth","family":"Laryea","sequence":"additional","affiliation":[{"name":"Korle Bu Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Caronni","sequence":"additional","affiliation":[{"name":"Fondazione Pezzoli per la Malattia di Parkinson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred Stephen","family":"Sarfo","sequence":"additional","affiliation":[{"name":"Komfo Anokye Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Del","family":"Sorbo","sequence":"additional","affiliation":[{"name":"Gaetano Pini-CTO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Fahn","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Pezzoli","sequence":"additional","affiliation":[{"name":"Fondazione Pezzoli per la Malattia di Parkinson"},{"name":"Gaetano Pini-CTO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3299"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21153"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28669"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12294"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12682"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30195-4"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.1783"},{"key":"e_1_3_3_10_2","article-title":"Availability of Parkinson\u2019s disease medicines in Ghana: a national survey [abstract]","volume":"34","author":"Cham M","year":"2019","unstructured":"Cham M, Sefah I, Oppon K, et al. Availability of Parkinson\u2019s disease medicines in Ghana: a national survey [abstract]. Mov Disord 2019; 34. https:\/\/www.mdsabstracts.org\/abstract\/availabilityof-parkinsons-disease-medicines-in-ghana-a-nationalsurvey\/ (accessed 20 December 2024).","journal-title":"Mov Disord"},{"key":"e_1_3_3_11_2","volume-title":"Improving access to medicines for neurological disorders","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Improving access to medicines for neurological disorders. Geneva: World Health Organization, 2024, Licence: CC BY-NC-SA 3.0 IGO. ISBN:978-92-4-009737-7."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00371-5"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.03.002"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106983"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004175"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.01.014"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.04.001"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)92729-3"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2217\/nmt.11.28"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/26.5.353"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21586"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033447"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.112.1.155"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000455863"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-02914-2"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03414-0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196902132800701"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1971.03190260019005"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251383721","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X251383721","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X251383721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:12:20Z","timestamp":1780683140000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X251383721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/1877718X251383721"],"URL":"https:\/\/doi.org\/10.1177\/1877718x251383721","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}